Got $1,500? Buy These 2 Surging Growth Stocks
In today's bearish market, consistent growth is hard to come by, but it still exists. With its shares up over 142% so far this year, it's a safe bet to call Veru (NASDAQ: VERU) a growth stock that's on a tear. The answer is that Veru is developing a treatment for severe COVID-19 called sabizabulin, and it's currently waiting on the final stamp of approval from regulators at the Food and Drug Administration (FDA).